Thomas A Desautels, Kathryn T Arrildt, Adam T Zemla, Edmond Y Lau, Fangqiang Zhu, Dante Ricci, Stephanie Cronin, Seth J Zost, Elad Binshtein, Suzanne M Scheaffer, Bernadeta Dadonaite, Brenden K Petersen, Taylor B Engdahl, Elaine Chen, Laura S Handal, Lynn Hall, John W Goforth, Denis Vashchenko, Sam Nguyen, Dina R Weilhammer, Jacky Kai-Yin Lo, Bonnee Rubinfeld, Edwin A Saada, Tracy Weisenberger, Tek-Hyung Lee, Bradley Whitener, James B Case, Alexander Ladd, Mary S Silva, Rebecca M Haluska, Emilia A Grzesiak, Christopher G Earnhart, Svetlana Hopkins, Thomas W Bates, Larissa B Thackray, Brent W Segelke, Antonietta Maria Lillo, Shivshankar Sundaram, Jesse D Bloom, Michael S Diamond, James E Crowe, Robert H Carnahan, Daniel M Faissol
The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs1-3 and revealed how quickly viral escape can curtail effective options4,5 . When the SARS-CoV-2 Omicron variant emerged in 2021, many antibody drug products lost potency, including Evusheld and its constituent, cilgavimab4-6 . Cilgavimab, like its progenitor COV2-2130, is a class 3 antibody that is compatible with other antibodies in combination4 and is challenging to replace with existing approaches...
May 8, 2024: Nature